Podcast
MSL Talk: Tom Caravela, Giovanni Passiatore
3 Things I wish I knew about being a MSL
Summary
In this episode, Tom Caravela welcomes Mitchell D’Rozario from Genentech Roche to share his journey into the MSL role. Mitchell provides three key insights he wishes he had known before becoming an MSL and poses thought-provoking questions to Tom. The discussion covers staying motivated and purpose-driven, exploring alternative career paths in the pharmaceutical industry, and the challenges of building relationships in a virtual environment. They also delve into the changing landscape of conferences and the importance of face-to-face interactions. The episode concludes with closing remarks, gratitude, and a request for subscription and feedback.
My guest today is Mitchell D’Rozario, Medical Science Liaison at Genentech and we discuss the 3 things he wished he knew about being an MSL.
In this episode we discuss:
- Mitchell’s background and breaking into the industry
- 3 things he wishes he had known about being an MSL
- What Tom wishes aspiring MSLs knew about the role
- What Tom looks for when screening candidates for roles
- Some red flags Tom notices often
- What keeps Mitchell on track
- What Mitchell learned in 2020 going through pandemic and how it changed him as an MSL
- His opinion of what 2021 will look like for field medical and what MSLs might expect
MSL career insights, pharmaceutical industry careers, virtual relationship building, Medical Science Liaison challenges, conference networking importance
Related Topics
You May Also Like
MSL Talk: Tom Caravela, Giovanni Passiatore
Article
Omer Ben‐Aharon, Racheli Magnezi, Moshe Leshno, and Daniel A. Goldstein
Median Survival or Mean Survival: Which Measure Is the Most Appropriate for Patients, Physicians, and Policymakers?
Press Release
OVN Staff
Announcing the Launch of Voices of Oncology: A Landmark Collaboration with Forbes
Press Release
OVN Staff
Introducing OncologyVoiceNetwork.com
Article
A. Haslam, M.S. Kim, V. Prasad
Updated estimates of eligibility for and response to genome-targeted oncology drugs among US cancer patients, 2006-2020
Podcast
MSL Talk: Tom Caravela, Sarah Snyder